trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['t-dxd', 'lcsm,(-blcsm)', 'lung']
different rates on ild due to t-dxd in lung cancer. more astringent patient selection? better side effect adjudication? better tolerability? better recognition by physicians and early treatment? we need larger numbers and more knowledge on this side effect. #lcsm #esmo22 
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm